Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UK55
UPID:
ZPI_HUMAN
Alternative names:
Serpin A10
Alternative UPACC:
Q9UK55; A5Z2A5; Q6UWX9; Q86U20
Background:
Protein Z-dependent protease inhibitor, also known as Serpin A10, plays a crucial role in blood coagulation. It inhibits the activity of coagulation protease factor Xa in the presence of PROZ, calcium, and phospholipids, and also inhibits factor XIa in the absence of cofactors. This regulatory mechanism is vital for maintaining hemostatic balance.
Therapeutic significance:
Understanding the role of Protein Z-dependent protease inhibitor could open doors to potential therapeutic strategies. Its pivotal function in coagulation and hemostasis suggests that targeting this protein could lead to novel treatments for clotting disorders.